Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …

Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic …

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations
across multiple cancer types including both solid and hematologic malignancies has …

Alterations to genes involved in cellular metabolism and epigenetic regulation are
implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate …

Eukaryotic cells compartmentalize biochemical processes in different organelles, often
relying on metabolic cycles to shuttle reducing equivalents across intracellular membranes …

Abstract Isocitrate dehydrogenase 1 mutations (mIDH1) are common in
cholangiocarcinoma.(R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits …

Mutations in metabolic enzymes, including isocitrate dehydrogenase 1 (IDH1) and IDH2, in
cancer strongly implicate altered metabolism in tumorigenesis. IDH1 and IDH2 catalyze the …

The coenzyme nicotinamide adenine dinucleotide phosphate (NADP+) and its reduced form
(NADPH) regulate reductive metabolism in a subcellularly compartmentalized manner …

Somatic mutations in cytosolic or mitochondrial isoforms of isocitrate dehydrogenase (IDH1
or IDH2, respectively) contribute to oncogenesis via production of the metabolite 2 …